Payment overview · 2025
General Payments
$373.07
21 reported records · 6 companies
Healthcare provider profile · identity verified
Christopher C Peterson, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SAN ANGELO, TX · NPI 1164535282
Verified facts
What the public records show
CMS Open Payments records show Christopher C Peterson, M.D. received $373.07 in general payments during 2025 across 21 reported records.
Sumitomo Pharma America, Inc. accounted for 52.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Ozempic, Trelegy Ellipta.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 292 claims for Ozempic by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $195.60 | 52.4% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $52.19 | 14.0% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $45.41 | 12.2% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $38.43 | 10.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.83 | 5.8% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $19.61 | 5.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $373.07 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $195.60 | 11 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $38.43 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $38.43 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $31.78 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $31.38 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $31.38 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $21.83 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $20.41 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $19.61 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 292 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
89 | 30 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
66 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
292 | 47 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 639 | 190 |
| Levothyroxine Sodium | Levothyroxine Sodium | 602 | 157 |
| Montelukast Sodium | Montelukast Sodium | 595 | 205 |
| Tramadol Hcl | Tramadol Hcl | 452 | 94 |
| Lisinopril | Lisinopril | 442 | 129 |
| Atorvastatin Calcium | Atorvastatin Calcium | 438 | 138 |
| Pantoprazole Sodium | Pantoprazole Sodium | 390 | 117 |
| Amlodipine Besylate | Amlodipine Besylate | 321 | 95 |
| Celecoxib | Celecoxib | 313 | 97 |
| Ozempic | Semaglutide | 292 | 47 |
| Potassium Chloride | Potassium Chloride | 252 | 74 |
| Gabapentin | Gabapentin | 247 | 69 |
| Omeprazole | Omeprazole | 244 | 73 |
| Tamsulosin Hcl | Tamsulosin Hcl | 233 | 80 |
| Hydrochlorothiazide | Hydrochlorothiazide | 232 | 72 |
| Losartan Potassium | Losartan Potassium | 223 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 217 | 59 |
| Zolpidem Tartrate | Zolpidem Tartrate | 210 | 47 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 205 | 141 |
| Carvedilol | Carvedilol | 178 | 53 |
| Allopurinol | Allopurinol | 172 | 54 |
| Furosemide | Furosemide | 165 | 64 |
| Sertraline Hcl | Sertraline Hcl | 162 | 47 |
| Eliquis | Apixaban | 158 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 151 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 150 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 149 | 43 |
| Metformin Hcl | Metformin Hcl | 140 | 45 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 136 | 28 |
| Alprazolam | Alprazolam | 131 | 35 |
| Trazodone Hcl | Trazodone Hcl | 131 | 35 |
| Simvastatin | Simvastatin | 122 | 38 |
| Azelastine Hcl | Azelastine Hcl | 115 | 54 |
| Spironolactone | Spironolactone | 113 | 37 |
| Doxycycline Hyclate | Doxycycline Hyclate | 110 | 84 |
| Meloxicam | Meloxicam | 109 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 107 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 105 | 33 |
| Eszopiclone | Eszopiclone | 96 | 27 |
| Pregabalin | Pregabalin | 93 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 92 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 89 | 31 |
| Myrbetriq | Mirabegron | 89 | 30 |
| Ezetimibe | Ezetimibe | 88 | 31 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 86 | 18 |
| Doxazosin Mesylate | Doxazosin Mesylate | 81 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 78 | 25 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 77 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 76 | 21 |
| Methocarbamol | Methocarbamol | 74 | 39 |
| Dutasteride | Dutasteride | 72 | 18 |
| Cephalexin | Cephalexin | 70 | 56 |
| Warfarin Sodium | Warfarin Sodium | 70 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 67 | 18 |
| Methylprednisolone | Methylprednisolone | 67 | 53 |
| Jardiance | Empagliflozin | 66 | 21 |
| Prednisone | Prednisone | 65 | 38 |
| Synthroid | Levothyroxine Sodium | 65 | 21 |
| Nifedipine Er | Nifedipine | 64 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 63 | 17 |
| Clonazepam | Clonazepam | 62 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 58 | 46 |
| Bupropion Xl | Bupropion Hcl | 57 | 16 |
| Diazepam | Diazepam | 57 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 56 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 56 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 55 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 55 | 15 |
| Solifenacin Succinate | Solifenacin Succinate | 55 | 16 |
| Azithromycin | Azithromycin | 54 | 50 |
| Fenofibrate | Fenofibrate | 54 | 13 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 54 | 14 |
| Memantine Hcl | Memantine Hcl | 54 | suppressed |
| Trulicity | Dulaglutide | 54 | suppressed |
| Baclofen | Baclofen | 53 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 53 | 18 |
| Buspirone Hcl | Buspirone Hcl | 52 | 13 |
| Finasteride | Finasteride | 52 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 51 | 13 |
| Lidocaine | Lidocaine | 51 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 51 | 15 |
| Benazepril Hcl | Benazepril Hcl | 49 | 16 |
| Estradiol | Estradiol | 49 | 14 |
| Mirtazapine | Mirtazapine | 48 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 44 | 13 |
| Metformin Hcl Er | Metformin Hcl | 43 | 14 |
| Alendronate Sodium | Alendronate Sodium | 42 | 14 |
| Januvia | Sitagliptin Phosphate | 42 | 12 |
| Lovastatin | Lovastatin | 42 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 42 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 41 | 37 |
| Topiramate | Topiramate | 41 | 15 |
| Dexlansoprazole Dr | Dexlansoprazole | 39 | 11 |
| Atenolol | Atenolol | 38 | 13 |
| Donepezil Hcl | Donepezil Hcl | 38 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 30 |
| Ipratropium Bromide | Ipratropium Bromide | 37 | 18 |
| Symbicort | Budesonide/Formoterol Fumarate | 37 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 36 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 35 | 35 |
| Tresiba Flextouch U-200 | Insulin Degludec | 33 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Linzess | Linaclotide | 31 | suppressed |
| Novolog Flexpen | Insulin Aspart | 31 | suppressed |
| Ciclopirox | Ciclopirox | 30 | suppressed |
| Glipizide | Glipizide | 30 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | suppressed |
| Torsemide | Torsemide | 27 | suppressed |
| Metaxalone | Metaxalone | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | suppressed |
| Famotidine | Famotidine | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 24 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 24 | suppressed |
| Gemfibrozil | Gemfibrozil | 23 | suppressed |
| Metronidazole | Metronidazole | 23 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Premarin | Estrogens, Conjugated | 23 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 21 | 13 |
| Ramipril | Ramipril | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | 15 |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 16 |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | 12 |
| Valsartan | Valsartan | 20 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 19 | suppressed |
| Scopolamine | Scopolamine | 19 | 16 |
| Ibandronate Sodium | Ibandronate Sodium | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Lubiprostone | Lubiprostone | 18 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Gemtesa | Vibegron | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 14 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Mirabegron Er | Mirabegron | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Novolin N Flexpen | Insulin Nph Human Isophane | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 12 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 12 | 12 |
| Propafenone Hcl | Propafenone Hcl | 12 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $373.07 · 21 records | Sumitomo Pharma America, Inc. | BREZTRI, FARXIGA, GEMTESA, MOUNJARO, Ozempic, Rybelsus, TRELEGY ELLIPTA, Veozah, Wegovy, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error